Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MIRA Pharmaceuticals, Inc. (MIRA : NSDQ)

• Company Description    MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.45 Daily Weekly Monthly 20 Day Moving Average: 190,460 shares Shares Outstanding: 19.07 (millions) Market Capitalization: $27.65 (millions) Beta: 1.75 52 Week High: $2.56 52 Week Low: $0.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.36% -3.09% 12 Week 17.89% 7.08% Year To Date 27.19% 30.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 BRICKELL AVENUE SUITE 1950 #1183 - MIAMI,FL 33131 USA ph: 786-432-9792 fax: - info@mirapharma.com https://mirapharmaceuticals.com

• General Corporate Information    Officers Erez Aminov - Chief Executive Officer and Chairman Michelle Yanez - Chief Financial Officer; Secretary and Treasurer Matthew Whalen - Director Matthew Del Giudice - Director Denil Shekhat - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 60458C104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 19.07 Most Recent Split Date: (:1) Beta: 1.75 Market Capitalization: $27.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 48.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.18% vs. Previous Quarter: 18.18% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -406.70 03/31/25 - -341.08 12/31/24 - -281.72 ROA 06/30/25 - -328.44 03/31/25 - -272.93 12/31/24 - -224.13 Current Ratio 06/30/25 - 2.80 03/31/25 - 12.86 12/31/24 - 3.99 Quick Ratio 06/30/25 - 2.80 03/31/25 - 12.86 12/31/24 - 3.99 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.03 03/31/25 - 0.08 12/31/24 - 0.13 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©